Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 8/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | TACR3 | P29371 | 1/20 | 0.33 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19430148 | 0.87 | TACR3 (0.42) | AOC3TRPM8TACR3 | |
| SCHEMBL19430222 | 0.86 | AOC3 (0.42) | AOC3CARM1TRPM8PRMT6PRMT8 | |
| SCHEMBL19430265 | 0.85 | AOC3 (0.37) | AOC3CARM1PRMT6PRMT8PRMT1 | |
| SCHEMBL19430304 | 0.85 | SCD5 (0.39) | AOC3 | |
| SCHEMBL19429870 | 0.85 | AOC3 (0.39) | AOC3CARM1PRMT1 | |
| SCHEMBL19430078 | 0.85 | AOC3 (0.38) | AOC3 | |
| SCHEMBL19430290 | 0.84 | AOC3 (0.36) | AOC3CARM1PLATPRMT1 | |
| SCHEMBL19429853 | 0.83 | AOC3 (0.41) | AOC3 | |
| SCHEMBL19430262 | 0.83 | AOC3 (0.37) | AOC3PRMT6PLAT | |
| SCHEMBL19430232 | 0.83 | AOC3 (0.40) | AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | AOC3 2654/4885CARM1 11/4885TRPM8 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.